Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose 4-way crossover pharmacokinetic study of oral and intravenous esketamine in healthy volunteers
NL-OMON43097Active, not recruiting
- Sponsor
- CIMA Labs
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of esketamine in major depressive disorder (MDD), sponsored by CIMA Labs. Primary endpoints: Safety and tolerability after oral and intravenous administration of esketamine, Pharmacokinetics of esketamine and metabolites and 4 more. Started Sep 2016; status: active, not recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON43097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43097.